15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and cell culture studies identified two thiazolidinedione-based dual inhibitors of tau-aggregation and GSK3B that could help treat AD. Chemical synthesis and in vitro testing in enzymatic activity assays of 35...
18:26 , Jun 13, 2018 |  BC Innovations  |  Distillery Techniques

Other

TECHNOLOGY: Computational models A method for designing small molecules that bind two protein targets could be used to generate dual inhibitors. The method utilizes in silico docking of a library of drug-like compounds and compound fragments...
16:17 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

Eisai Co. Ltd. (Tokyo:4523) and Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) reported preliminary data from a Phase II/III trial in about 410 Parkinson's disease patients with wearing-off phenomenon showing that once-daily 50 and 100...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
18:43 , Jul 6, 2017 |  BC Week In Review  |  Clinical News

Takeda submits Japanese NDA for rasagiline to treat PD

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an NDA in Japan for Azilect rasagiline mesylate (TVP-1012) to treat Parkinson’s disease (PD). The product is an irreversible selective inhibitor of monoamine oxidase B (MAO-B). In 2014, Teva Pharmaceutical...
20:53 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

Xadago regulatory update

FDA approved an NDA for Xadago safinamide from Newron as an add-on treatment for patients with Parkinson's disease (PD) who are currently taking levodopa/carbidopa and experiencing "off" episodes. In March 2016, FDA issued a complete...
23:11 , Mar 21, 2017 |  BC Extra  |  Company News

FDA approves Newron's Xadago

FDA approved Xadago safinamide from Newron Pharmaceuticals S.p.A. (SIX:NWRN) as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and experiencing "off" episodes. In March 2016, FDA issued a complete response letter...
19:59 , Jan 20, 2017 |  BC Week In Review  |  Company News

Zambon, CSL deal

Zambon granted CSL’s Seqirus unit exclusive rights to develop and commercialize Parkinson’s disease drug Xadago safinamide in Australia and New Zealand. Zambon has exclusive rights from Newron Pharmaceuticals S.p.A. (SIX:NWRN, Bresso, Italy) to develop and...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Clinical News

Xadago safinamide regulatory update

Newron said FDA accepted a resubmitted NDA for Xadago safinamide from Newron as an add-on therapy for early and mid- to late-stage Parkinson’s disease (PD). The PDUFA date is March 21, 2017. In March, FDA...
07:00 , Oct 21, 2016 |  BC Extra  |  Company News

FDA again reviewing Newron's Xadago for Parkinson's

Newron Pharmaceuticals S.p.A. (SIX:NWRN) said FDA accepted its re-submitted NDA for Parkinson's disease candidate Xadago safinamide. Its PDUFA date is March 21, 2017. In March, the agency issued a complete response letter for the compound,...